Equities researchers at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The company’s 50 day simple moving average is $0.14. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. The stock has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53.
Nabriva Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 6/24 – 6/28
- Investing in large cap stocks: Diving into big caps
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.